A genetic profiling guideline to support diagnosis and clinical management of lymphomas

[1]  F. Climent,et al.  Extranodal natural killer/T‐cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets , 2023, American journal of hematology.

[2]  A. Dogan,et al.  Mature T-cell and NK-cell lymphomas: updates on molecular genetic features , 2023, International Journal of Hematology.

[3]  T. Baumann,et al.  Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT , 2023, Leukemia.

[4]  P. Gaulard,et al.  Extranodal T- and NK-cell lymphomas , 2022, Virchows Archiv.

[5]  W. Chan,et al.  Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas , 2022, Virchows Archiv.

[6]  Ash A. Alizadeh,et al.  Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms. , 2022, Blood.

[7]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[8]  L. Staudt,et al.  The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. , 2022, Blood.

[9]  P. Jain,et al.  Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments , 2022, American journal of hematology.

[10]  Yeon Jeong Kim,et al.  Circulating Tumor DNA–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas , 2022, Cancer research and treatment.

[11]  Peggy Wu,et al.  T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  C. Ong,et al.  Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS , 2022, Haematologica.

[13]  H. Holte,et al.  Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. , 2021, Blood.

[14]  L. Leoncini.  Epstein–Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes , 2021, British journal of haematology.

[15]  S. Turner,et al.  Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma , 2021, Leukemia.

[16]  M. Hallek,et al.  Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures , 2021, American journal of hematology.

[17]  A. Evens,et al.  Defining and Treating High-grade B-cell lymphoma, NOS. , 2021, Blood.

[18]  E. González-Barca,et al.  Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM) , 2021, PloS one.

[19]  D. Rossi,et al.  Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab , 2021, Blood advances.

[20]  A. Tzankov,et al.  Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin , 2021, Virchows Archiv.

[21]  J. Ule,et al.  Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. , 2021, Molecular cell.

[22]  O. Ohara,et al.  Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B‐cell lymphoma in a Japanese cohort , 2021, British journal of haematology.

[23]  P. Sujobert,et al.  How to Obtain a High Quality ctDNA in Lymphoma Patients: Preanalytical Tips and Tricks , 2021, Pharmaceuticals.

[24]  Ash A. Alizadeh,et al.  Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA , 2021, Nature Biotechnology.

[25]  P. Kwok,et al.  Integrated Genomic Analyses of Cutaneous T Cell Lymphomas Reveal the Molecular Bases for Disease Heterogeneity. , 2021, Blood.

[26]  A. López-Guillermo,et al.  Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. , 2021, Blood.

[27]  J. Zimmermann,et al.  Genomic insights into the pathogenesis of Epstein–Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing , 2021, Blood Cancer Journal.

[28]  M. Piris,et al.  Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy , 2021, Cancers.

[29]  K. Young,et al.  Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia , 2021, Neoplasia.

[30]  R. Küppers,et al.  Molecular biology of Hodgkin lymphoma , 2021, Leukemia.

[31]  Laura E. Brown,et al.  New developments in non-Hodgkin lymphoid malignancies. , 2021, Pathology.

[32]  Juan F. García,et al.  Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma , 2021, Scientific Reports.

[33]  C. Buske,et al.  CXCR4 in Waldenström’s Macroglobulinema: chances and challenges , 2020, Leukemia.

[34]  Š. Pospíšilová,et al.  STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma , 2020, Leukemia.

[35]  C. Copie-Bergman,et al.  Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. , 2020, Blood advances.

[36]  E. Campo,et al.  IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. , 2020, Blood.

[37]  E. Chapiro,et al.  The complex karyotype and chronic lymphocytic leukemia. A review of the literature. , 2020, American journal of hematology.

[38]  E. Campo,et al.  Molecular Pathogenesis of Mantle Cell Lymphoma. , 2020, Hematology/oncology clinics of North America.

[39]  Ali F. Alsulami,et al.  Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target , 2020, Haematologica.

[40]  Ryan D. Morin,et al.  A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. , 2020, Cancer cell.

[41]  S. Barrans,et al.  Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. , 2020, Blood.

[42]  A. Salar,et al.  Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  E. Kimby,et al.  M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy , 2020, British journal of haematology.

[44]  M. Darweesh,et al.  Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade , 2019, Hematological oncology.

[45]  S. Barrans,et al.  Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit , 2019, Leukemia.

[46]  Yuri Fedoriw,et al.  Pathology and diagnosis of follicular lymphoma and related entities. , 2019, Pathology.

[47]  S. Hartmann,et al.  Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma. , 2019, Pathology.

[48]  A. López-Guillermo,et al.  IRF4-rearranged Large B-cell lymphoma (LBCL) has a genomic profile distinct to other LBCL in children and young adults. , 2019, Blood.

[49]  J. Bailey,et al.  The whole genome landscape of Burkitt lymphoma subtypes. , 2019, Blood.

[50]  D. Rossi,et al.  KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study , 2019, Haematologica.

[51]  L. Bullinger,et al.  Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia , 2019, Haematologica.

[52]  P. Feugier,et al.  Prevalence of BTK and PLCG2 mutations in a real‑life CLL cohort still on ibrutinib after three years: a FILO group study. , 2019, Blood.

[53]  Michael R. Green,et al.  Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma , 2019, bioRxiv.

[54]  S. Pileri,et al.  Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified , 2019, Modern Pathology.

[55]  L. Staudt,et al.  Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. , 2019, Blood.

[56]  O. Dereure,et al.  Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior , 2019, Virchows Archiv.

[57]  Jules N. A. Kerssemakers,et al.  Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma , 2019, Nature Communications.

[58]  Steven J. M. Jones,et al.  Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. , 2019, Blood.

[59]  Juan F. García,et al.  Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma , 2019, Blood Cancer Journal.

[60]  S. Bens,et al.  The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. , 2019, Blood.

[61]  Juan F. García,et al.  Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma , 2019, PloS one.

[62]  I. Gut,et al.  Clonal dynamics monitoring during clinical evolution in chronic lymphocytic leukaemia , 2019, Scientific Reports.

[63]  A. Bordron,et al.  17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia , 2019, Journal of Immunotherapy for Cancer.

[64]  P. Gaulard,et al.  Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas , 2019, Leukemia.

[65]  L. Bullinger,et al.  Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells. , 2018, Blood.

[66]  M. Shahjahani,et al.  The role of the genetic abnormalities, epigenetic and microRNA in the prognosis of chronic lymphocytic leukemia. , 2018, Experimental oncology.

[67]  A. Rosenwald,et al.  Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. , 2018, Blood.

[68]  Michael L. Wang,et al.  Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib , 2018, British journal of haematology.

[69]  A. Feldman,et al.  Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. , 2018, Blood.

[70]  Alexander V Penson,et al.  Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. , 2018, Blood.

[71]  F. Cavalli,et al.  Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. , 2018, Blood.

[72]  E. Campo,et al.  Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. , 2018, Blood.

[73]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[74]  L. de Leval,et al.  Dual JAK1 and STAT3 mutations in a breast implant-associated anaplastic large cell lymphoma , 2018, Virchows Archiv.

[75]  L. Medeiros,et al.  Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. , 2018, Human pathology.

[76]  C. Thieblemont.  Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. , 2017, Hematology. American Society of Hematology. Education Program.

[77]  M. Davids,et al.  IGHV mutational status testing in chronic lymphocytic leukemia , 2017, American journal of hematology.

[78]  Juan F. García,et al.  Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets , 2017, Oncotarget.

[79]  Juan F. García,et al.  Mutational profile of primary breast diffuse large B-cell lymphoma , 2017, Oncotarget.

[80]  Marc L. Mendillo,et al.  Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). , 2017, Blood.

[81]  J. D. van der Walt,et al.  Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. , 2017, Blood.

[82]  R. Advani,et al.  Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. , 2017, Blood.

[83]  R. Foà,et al.  Diffuse large B-cell lymphoma genotyping on the liquid biopsy. , 2017, Blood.

[84]  P. Gaulard,et al.  Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin , 2017, Haematologica.

[85]  M. Du.  MALT lymphoma: Genetic abnormalities, immunological stimulation and molecular mechanism. , 2017, Best practice & research. Clinical haematology.

[86]  Ali Bashashati,et al.  Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study , 2016, PLoS medicine.

[87]  Ash A. Alizadeh,et al.  Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA , 2016, Science Translational Medicine.

[88]  Gisela Mir Arnau,et al.  Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma , 2016, Haematologica.

[89]  A. Prasad,et al.  Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome. , 2016, The Journal of investigative dermatology.

[90]  F. Bosch,et al.  A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia , 2016, Hematological oncology.

[91]  Ryan D. Morin,et al.  Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations , 2016, Oncotarget.

[92]  E. Zucca,et al.  The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. , 2016, Blood.

[93]  P. Gaulard,et al.  Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  A. Ferrando,et al.  The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome , 2015, Nature Genetics.

[95]  M. Pedersen,et al.  Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  M. Sánchez-Beato,et al.  Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. , 2015, Cancer treatment reviews.

[97]  D. Schatz,et al.  Genomic landscape of cutaneous T cell lymphoma , 2015, Nature Genetics.

[98]  Ash A. Alizadeh,et al.  Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation , 2015, Proceedings of the National Academy of Sciences.

[99]  O. Elemento,et al.  Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. , 2015, Blood.

[100]  Adrien B. Larsen,et al.  Loss of signaling via Gα13 in germinal center B cell-derived lymphoma , 2014, Nature.

[101]  W. Wilson,et al.  ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. , 2014, Blood.

[102]  I. Varela,et al.  PLCG1 mutations in cutaneous T-cell lymphomas. , 2014, Blood.

[103]  Raul Rabadan,et al.  Genetics of follicular lymphoma transformation. , 2014, Cell reports.

[104]  M. Calaminici,et al.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.

[105]  Raul Rabadan,et al.  Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome , 2013, The Journal of experimental medicine.

[106]  Manel Juan,et al.  Landscape of somatic mutations and clonal evolution in mantle cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[107]  W. Chan,et al.  Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. , 2013, Blood.

[108]  Ash A. Alizadeh,et al.  Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. , 2012, Blood.

[109]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[110]  L. Staudt,et al.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.

[111]  D. Pisano,et al.  New Mutations in Chronic Lymphocytic Leukemia Identified by Target Enrichment and Deep Sequencing , 2012, PloS one.

[112]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[113]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[114]  Steven J. M. Jones,et al.  MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers , 2011, Nature.

[115]  A. López-Guillermo,et al.  Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[116]  S. Pileri,et al.  Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. , 2010, Blood.

[117]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[118]  A. Pettitt,et al.  TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations , 2010, Leukemia.

[119]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[120]  R. Gascoyne,et al.  Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. , 2010, Blood.

[121]  L. Pasqualucci,et al.  The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. , 2008, Blood.

[122]  L. Staudt,et al.  Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. , 2007, Blood.

[123]  R. Siebert,et al.  Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma , 2006, Leukemia.

[124]  Gerard Lozanski,et al.  Adult Burkitt leukemia and lymphoma. , 2004, Blood.

[125]  M. Piris,et al.  Molecular heterogeneity of splenic marginal zone lymphomas: analysis of mutations in the 5′ non-coding region of the bcl-6 gene , 2001, Leukemia.

[126]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[127]  M. Piris,et al.  Epstein-Barr Virus-Latent Membrane Protein 1 Expression Has a Favorable Influence in the Outcome of Patients with Hodgkin's Disease Treated with Chemotherapy , 2000, Leukemia & lymphoma.

[128]  J. Vose,et al.  T-Cell Lymphomas in South America and Europe , 2012, Revista brasileira de hematologia e hemoterapia.